ID
16691
Descripción
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Screening Assessments
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Palabras clave
Versiones (2)
- 27/7/16 27/7/16 -
- 1/8/16 1/8/16 -
Subido en
1 de agosto de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Screening Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Screening Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Descripción
Demographics
Descripción
Date of birth
Tipo de datos
date
Alias
- UMLS CUI [1]
- C0421451
Descripción
Gender
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0079399
Descripción
Ethnicity
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0015031
Descripción
Race
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C0034510
Descripción
Race
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0034510
Descripción
Screening Eligibility Criteria
Descripción
Inclusion Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1512693
Descripción
Inclusion Criteria
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1512693
Descripción
Exclusion Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0680251
Descripción
Exclusion Criteria
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0680251
Descripción
Eligibility Criteria
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Descripción
Date screening consent was signed
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0021430
Descripción
IVRS Screening Number
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1710477
Descripción
Treatment Eligibility Criteria
Descripción
Inclusion Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1512693
Descripción
Inclusion Criteria
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1512693
Descripción
Exclusion Criteria
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0680251
Descripción
Exclusion Criteria
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0680251
Descripción
Eligibility Criteria
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Descripción
Date main study consent was signed
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0021430
Descripción
IVRS Randomization
Similar models
Screening Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0600091 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,2])
Sin comentarios